^
    1d
    ACADEMY: A Trial of Apatinib and Adebrelimab in Combination With Chemotherapy in Patients With Unresectable ICC (clinicaltrials.gov)
    P2, N=38, Recruiting, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Trial completion date: Oct 2027 --> Oct 2028 | Trial primary completion date: Jun 2026 --> Jun 2027
    Trial completion date • Trial primary completion date
    |
    AiTan (rivoceranib) • AiRuiLi (adebrelimab)
    2d
    ESCC-PT: Precision Medicine for Immunotherapy-Resistant Advanced Esophageal Cancer (clinicaltrials.gov)
    P2/3, N=90, Not yet recruiting, Peking University Cancer Hospital & Institute
    New P2/3 trial • Checkpoint inhibition
    |
    PD-L1 (Programmed death ligand 1)
    |
    Gilotrif (afatinib) • Loqtorzi (toripalimab-tpzi) • AiRuiKa (camrelizumab) • AiTan (rivoceranib) • Irene (pyrotinib) • AiRuiKang (dalpiciclib)
    7d
    A Phase Ib/II Clinical Study of Camrelizumab and Apatinib Plus GP in the Treatment of Advanced Biliary Tract Cancer (clinicaltrials.gov)
    P1/2, N=48, Completed, Sun Yat-sen University | Not yet recruiting --> Completed | Trial completion date: Dec 2024 --> May 2026 | Trial primary completion date: Dec 2023 --> Dec 2025
    Trial completion • Trial completion date • Trial primary completion date
    |
    cisplatin • gemcitabine • AiRuiKa (camrelizumab) • AiTan (rivoceranib)
    7d
    A Real-world Study of Immunotherapy Combination Regimens for Treating Liver Cancer in Cold Regions (clinicaltrials.gov)
    P=N/A, N=1000, Active, not recruiting, Harbin Medical University
    New trial • Real-world evidence
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Avastin (bevacizumab) • Tecentriq (atezolizumab) • sorafenib • Tyvyt (sintilimab) • AiRuiKa (camrelizumab) • AiTan (rivoceranib) • oxaliplatin • Zepsun (donafenib)
    9d
    The Application of Locoregional Therapy Combined With Systemic Therapy in the Perioperative Period of Huge Hepatocellular Carcinoma: A Retrospective Cohort Study (clinicaltrials.gov)
    P=N/A, N=715, Completed, Tongji Hospital
    New trial
    |
    Keytruda (pembrolizumab) • Avastin (bevacizumab) • Tecentriq (atezolizumab) • sorafenib • Tyvyt (sintilimab) • AiRuiKa (camrelizumab) • Tevimbra (tislelizumab-jsgr) • AiTan (rivoceranib) • Stivarga (regorafenib) • Zepsun (donafenib)
    15d
    SYSKY-2023-1262-02: Combination Immunotherapy of Adebrelimab With Apatinib and Tegafur, Gimeracil and Oteracil Potassium Capsules for Immune Rechallenge Therapy in Esophageal Squamous Cell Carcinoma (clinicaltrials.gov)
    P2, N=32, Recruiting, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Trial completion date: Sep 2026 --> Sep 2028 | Trial primary completion date: Mar 2026 --> Mar 2028
    Trial completion date • Trial primary completion date
    |
    AiTan (rivoceranib) • Teysuno (gimeracil/oteracil/tegafur) • AiRuiLi (adebrelimab)
    16d
    Apatinib inhibits synovial sarcoma progression and angiogenesis via VEGFR2-mediated AKT/FOXO3A and ERK1/2/FOXM1 signaling pathways. (PubMed, Cell Death Discov)
    In vivo, apatinib markedly suppressed xenograft tumor growth and modulated the corresponding signaling pathways. Collectively, our findings identify apatinib as a promising therapeutic agent that disrupts interconnected survival and angiogenic networks in SS.
    Journal
    |
    KDR (Kinase insert domain receptor) • FOXM1 (Forkhead Box M1) • FOXO3 (Forkhead box O3) • NOS3 (Nitric oxide synthase 3)
    |
    AiTan (rivoceranib)
    18d
    A Multicenter, Randomized, Open-label, Controlled Study of HAIC Combined With Camrelizumab and Apatinib Mesylate for Perioperative Treatment of Resectable Hepatocellular Carcinoma With High-risk Recurrence Factors (clinicaltrials.gov)
    P=N/A, N=208, Not yet recruiting, Henan Cancer Hospital
    New trial
    |
    AFP (Alpha-fetoprotein)
    |
    5-fluorouracil • AiRuiKa (camrelizumab) • AiTan (rivoceranib) • oxaliplatin • leucovorin calcium
    21d
    Metachronous hepatocellular carcinoma after partial response of advanced intrahepatic cholangiocarcinoma treated with radiotherapy combined with apatinib and camrelizumab: a case report. (PubMed, Front Oncol)
    Radiotherapy combined with anti-angiogenic and immunotherapy is an effective option for advanced unresectable iCCA. It also emphasizes that active pathological biopsy is essential for new hepatic lesions after iCCA remission to clarify diagnosis and avoid misdiagnosis-induced inappropriate treatment.
    Journal
    |
    AFP (Alpha-fetoprotein)
    |
    AiRuiKa (camrelizumab) • AiTan (rivoceranib)
    21d
    Apatinib enhances anti-PD-1 efficacy by inhibiting Exo70-mediated exosome secretion in pMMR/MSS colorectal cancer. (PubMed, NPJ Precis Oncol)
    This inhibitory effect was mediated through the regulation of Exo70. Collectively, our findings indicate that apatinib enhances the efficacy of camrelizumab in pMMR/MSS colorectal cancer and provide a theoretical rationale for the combined use of camrelizumab and apatinib in this patient population.
    Journal • pMMR
    |
    PD-L1 (Programmed death ligand 1)
    |
    AiRuiKa (camrelizumab) • AiTan (rivoceranib)
    22d
    FASCINATE-N: Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy (clinicaltrials.gov)
    P2, N=716, Recruiting, Fudan University | Trial completion date: Sep 2028 --> Sep 2029 | Trial primary completion date: Dec 2026 --> Dec 2027
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor) • CD8 (cluster of differentiation 8) • FOXC1 (Forkhead Box C1)
    |
    Herceptin (trastuzumab) • carboplatin • Focus V (anlotinib) • Perjeta (pertuzumab) • AiRuiKa (camrelizumab) • AiTan (rivoceranib) • Irene (pyrotinib) • albumin-bound paclitaxel • cyclophosphamide • letrozole • epirubicin • trastuzumab rezetecan (SHR-A1811) • AiRuiYi (fluzoparib) • Andewei (benmelstobart) • AiRuiKang (dalpiciclib) • goserelin acetate • famitinib (SHR 1020) • Idafang (ivonescimab) • bulumtatug fuvedotin (9MW2821) • AiRuiLi (adebrelimab) • IBI-354 • SHR-4602 • TQB2102 • TQB2868 • anbenitamab repodatecan (JSKN003) • tizetatug rezetecan (SHR-A1921)
    22d
    RA-A-NP: Retlirafusp Alfa Combined With Apatinib and Nab-Paclitaxel as Second-line Treatment for Gastric or Gastroesophageal Junction Cancer (clinicaltrials.gov)
    P2, N=50, Not yet recruiting, Henan Cancer Hospital
    New P2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    AiTan (rivoceranib) • albumin-bound paclitaxel • retlirafusp alfa (SHR-1701)